<DOC>
	<DOC>NCT00346294</DOC>
	<brief_summary>An open-label, single arm study to estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.</brief_summary>
	<brief_title>An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis of rheumatoid arthritis RA subjects 18 years or older Currently taking etanercept in prefilled syringes for at least 4 weeks Subjects must give written informed consent Subjects must be able to read and write in English Subject is not using adequate contraception Subject is pregnant or breast feeding Significant concurrent medical diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Device</keyword>
	<keyword>Auto-injector</keyword>
	<keyword>SureClick</keyword>
	<keyword>Enbrel</keyword>
	<keyword>Etanercept</keyword>
</DOC>